BioCentury
ARTICLE | Company News

MedImmune, Juno to test PD-L1/CAR T combo

April 24, 2015 1:50 AM UTC

Juno Therapeutics Inc. (NASDAQ:JUNO) and the MedImmune LLC unit of AstraZeneca plc (LSE:AZN; NYSE:AZN) entered a non-exclusive collaboration to study a combination of MedImmune's PD-L1 inhibitor MEDI4736 and a Juno chimeric antigen receptor (CAR) T cell therapy directed against CD-19.

MedImmune spokesperson Susannah Budington told BioCentury the companies plan to begin a Phase Ib study of the combination this year to treat non-Hodgkin's lymphoma (NHL). The parties said they will fund the trial jointly, but did not release specific financial terms. ...